Clinical trial · Observational
Human Liver Explants for HIF-1 Alpha Analysis/Comparison (HIF HCC)
Human Liver Explants for HIF-1 Alpha- Analysis/Comparison
NCT00866957CI-TRIAL-00071429completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to compare levels of HIF-1 α (Hypoxia Inducing Factor 1-alpha) in patients who have been treated with various types of liver cancer treatments.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood draw | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with liver cancer
- description
- Patients diagnosed with liver cancer
- interventionNames
- Procedure: Blood draw
Primary outcomes (1)
- measure
- HIF-1alpha bio-marker
- timeFrame
- December 2015
- description
- The primary objective is to compare levels of HIF-1alpha expression in HCC tumor explants which have received: 1) no pre-explant embolization; 2) pre-explant Transcatheter arterial chemoembolization (TACE); 3) pre-explant Y90 radio-embolization; 4) pre-explant radiofrequency ablation, or 5) a combination of pre-explant therapies.
Secondary outcomes (1)
- measure
- Understand biological behavior of the tumors
- timeFrame
- December 2015
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults, any gender ≥ to 18 years of age * Previous, or current diagnosis of hepatocellular carcinoma (clinical or biopsy proven) * Resection for hepatoma and/or transplant * Patients with diagnosis of hepatocellular carcinoma from 8/1/94 thru 12/31/05 (retrospective) with biopsy, explant and/or liver transplantation here at Northwestern Memorial Hospital (NMH). * Patients previously diagnosed or, recently diagnosed with liver cancer that were treated, currently are being treated our will potentially undergo treatment for the disease. Exclusion Criteria: * Any subject outside of the above inclusion criteria
References
Publications (32)
- BACKGROUNDKew MC. Epidemiology of hepatocellular carcinoma. Toxicology. 2002 Dec 27;181-182:35-8. doi: 10.1016/s0300-483x(02)00251-2. PMID 12505281
- BACKGROUNDDi Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S169-71. doi: 10.1016/s1051-0443(07)61783-7. PMID 12354833
- BACKGROUNDEl-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003 Nov 18;139(10):817-23. doi: 10.7326/0003-4819-139-10-200311180-00009. PMID 14623619
- BACKGROUNDMacdonald GA. Pathogenesis of hepatocellular carcinoma. Clin Liver Dis. 2001 Feb;5(1):69-85. doi: 10.1016/s1089-3261(05)70154-9. PMID 11218920
- BACKGROUNDMarcos-Alvarez A, Jenkins RL, Washburn WK, Lewis WD, Stuart KE, Gordon FD, Kane RA, Clouse ME. Multimodality treatment of hepatocellular carcinoma in a hepatobiliary specialty center. Arch Surg. 1996 Mar;131(3):292-8. doi: 10.1001/archsurg.1996.01430150070014. PMID 8611095
- BACKGROUNDOkada S, Okazaki N, Nose H, Yoshimori M, Aoki K. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology. 1992 Jul;16(1):112-7. doi: 10.1002/hep.1840160119. PMID 1377657
- BACKGROUNDColleoni M, Bajetta E, Nelli P, Boni L, Bochicchio AM, Nole F, Buzzoni R, Celio L, Mazzaferro V, Bonfanti G, et al. Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: the experience of the National Cancer Institute of Milan. Ann Oncol. 1993 Jun;4(6):489-93. doi: 10.1093/oxfordjournals.annonc.a058560. PMID 8394736
- Boucher E, Corbinais S, Brissot P, Boudjema K, Raoul JL. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol. 2002 Oct;50(4):305-8. doi: 10.1007/s00280-002-0503-x. Epub 2002 Aug 7.